Overview

Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis

Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Pharma Biotherapeutics USA Inc.